People · Operator

Vito J. Palombella

Named in public records as an officer, director or promoter · active 2012–2012 · Biotechnology

1
Companies
1
Filings
$78.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Infinity Pharmaceuticals, Inc.BiotechnologySeries C$78.5M$3.2B2012
Operator network

Vito J. Palombella at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Anthony B. Evnin · 4 companies · 1 sharedAnthony B. EvninNorman C. Selby · 4 companies · 1 sharedNorman C. SelbyThomas J. Lynch · 3 companies · 1 sharedThomas J. LynchGwen A. Fyfe · 2 companies · 1 sharedGwen A. FyfeIan F. Smith · 2 companies · 1 sharedIan F. SmithAdelene Q. Perkins · 1 companies · 1 sharedAdelene Q. PerkinsEric S. Lander · 1 companies · 1 sharedEric S. LanderJulian Q. Adams · 1 companies · 1 sharedJulian Q. AdamsMartin H Babler · 1 companies · 1 sharedMartin H BablerMichael C. Venuti · 1 companies · 1 sharedMichael C. VenutiPatrick P Lee · 1 companies · 1 sharedPatrick P LeePedro J. Santabarbara · 1 companies · 1 sharedPedro J. Santabar…Steve H Holtzman · 1 companies · 1 sharedSteve H HoltzmanInfinity Pharmaceuticals, Inc. · $78.5M raisedInfinity Pharmaceutic…Vito J. PalombellaVP
Vito J. Palombella Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Vito J. Palombella on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Norman C. Selby14
Anthony B. Evnin14
Thomas J. Lynch13
Ian F. Smith12
Gwen A. Fyfe12
Julian Q. Adams11
Michael C. Venuti11
Steve H Holtzman11
Pedro J. Santabarbara11
Eric S. Lander11
Patrick P Lee11
Adelene Q. Perkins11
Martin H Babler11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.